Squibb Diagnostics' Cardio Tec (Tc 99m teboroxime)
Radioactive forms of the myocardial perfusion agent will be distributed exclusively by radiopharmacies operator Syncor. Under the agreement, Squibb will sell non-radioactive forms of Cardio Tec to medical centers that perform their own radioactive compounding. Cardiotec was recommended for approval Nov. 17 by the FDA Radiopharmaceutical Committee for use in distinguishing normal from abnormal myocardium in patients with suspected coronary artery disease.
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.